TRICON8B is the translational research sub-study of the ICON8B trial. The aim is to establish a large, comprehensive biobank comprising tumour tissue, blood and serial plasma samples with associated clinical data which will be an invaluable resource for high-quality translational research in ovarian cancer. ICON8B is a phase III randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer.

Topics: